Structure Therapeutics Inc American Depositary Shares

Yahoo Finance • 2 months ago

Is Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now?

We recently compiled a list of 10 Best Young Stocks To Buy Now. In this article, we will look at where Structure Therapeutics Inc. (NASDAQ:GPCR) ranks among the best young stocks to buy now. Market Uncertainty to Remain Until Elections A... Full story

Yahoo Finance • 3 months ago

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Structure Therapeutics Inc. Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc.... Full story

Yahoo Finance • 3 months ago

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Structure Therapeutics Inc. SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and... Full story

Yahoo Finance • 4 months ago

Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.

With Eli Lilly up by a stunning 47% so far this year, many investors are likely prone to feeling they're stuck on the sidelines after this bull run. Even if there's plenty of upside left -- and in Eli Lilly's case, there almost certainly i... Full story

Yahoo Finance • 4 months ago

Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?

Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics? Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics Inc (NASDAQ:VKTX),... Full story

Yahoo Finance • 6 months ago

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Structure Therapeutics Inc. GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (p<0.0001) in the Phase 2a obesity study and up to 6.9% (p<0.0001) in the capsule to tablet PK... Full story